Compare Southwest Airlines Co (LUV) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs TG Therapeutics Inc — how do they compare? Southwest Airlines Co trades at $45.02 (market cap $22.27B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Southwest Airlines Co is far larger — about 2.9× TG Therapeutics Inc's market cap, and Southwest Airlines Co pays a 1.58% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| LUV | TGTX | |
|---|---|---|
Market Cap | $22.27B | $7.64B |
Sector | Industrials | Health |
52-Week High | $54.80 | $59.06 |
52-Week Low | $29.67 | $26.94 |
Enterprise Value | $25.37B | $7.84B |
Dividend Yield | 1.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $45.06, up 0.36% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings with $0.94 EPS beating expectations by 84%, while Q1 missed estimates. Revenue growth continues with 2026 projections at $30.1B, though net margins remain thin at 2.78%. Recent board appointments and business travel initiatives signal strategic focus on premium segments.
LUV presents a value opportunity with attractive P/S (0.79) and dividend yield, but faces headwinds from fuel cost volatility and competitive pressures. Analyst consensus targets $53.86 (20% upside) with mixed ratings. The stock's outlook hinges on sustained travel demand and effective cost management amid industry challenges.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
